What Is Foundayo?
Foundayo (orforglipron) won its UK licence on 10 August 2026 — the first small-molecule GLP-1 tablet, no fasting required. What it is, the trial data, and when you can actually get it.
What it is
Foundayo is the brand name for orforglipron, Eli Lilly's once-daily GLP-1 tablet — and on 10 August 2026 the UK became the first country in Europe to license it. Unlike every GLP-1 before it, orforglipron is a small molecule, not a peptide — which is why it needs no injections, no fridge, and no fasting routine.
How it works
It activates the same GLP-1 receptor as injectable medicines, reducing appetite and slowing digestion — but its small-molecule chemistry survives digestion far better than peptide tablets. Take it once a day, with or without food. That simplicity is the point.
What the trials show
In ATTAIN-1, adults on the highest dose lost an average of 11.2% of body weight over 72 weeks. Below Mounjaro's headline figures, above placebo by a wide margin — and the UK licence also covers weight maintenance after injectable treatment and type 2 diabetes, making it the natural “step-down” tablet.
The doses
Six strengths — 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg and 17.2mg — starting low and stepping up at intervals of at least a month, guided by a prescriber.
When can you actually get it?
Not quite yet on shelves: new approvals take a few weeks to filter through wholesalers to pharmacies. Pre-orders are open at some GPhC-registered providers, stock is expected to build over the coming weeks, and the NICE funding decision for NHS use is expected in November 2026. Manufacturing costs for small molecules run lower than peptides, so analysts expect competitive pricing — the live picture, the moment prices publish, is at Frayo.co.uk.
The honest caveats
Prescription-only, newer evidence base than semaglutide, and — being this year's headline medicine — an obvious target for counterfeit sellers. Verify any pharmacy on the GPhC register before parting with money; every provider in our directory links to its live register entry.
Quick answers.
What is Foundayo used for?
Foundayo (orforglipron) is licensed in the UK for weight management in adults with obesity, or overweight with a weight-related condition, alongside diet and activity changes. It is a prescription-only medicine supplied as a once-daily tablet, made by Eli Lilly.
Do I need a prescription for Foundayo in the UK?
Yes. Foundayo is prescription-only. Every legitimate UK provider — including all 105 in the Pharmacy Score directory — requires an online assessment reviewed by a qualified prescriber before dispensing.
Where can I find the best Foundayo price?
Live UK prices for Foundayo are tracked at Frayo.co.uk, covering GPhC-registered pharmacies. Pharmacy Score does not republish prices because they change too quickly to stay accurate.
How do I check a pharmacy selling Foundayo is legitimate?
Look up its premises number on the GPhC register at pharmacyregulation.org — every profile on Pharmacy Score links directly to the pharmacy's live register entry so you can verify in seconds.
The rest of the family.
The official sources, in one place.
These are the bodies that actually regulate, appraise and advise. If anything you read anywhere — including here — disagrees with them, believe them.